InvestorsHub Logo
Followers 10
Posts 1734
Boards Moderated 1
Alias Born 10/08/2011

Re: None

Wednesday, 05/01/2019 6:48:56 PM

Wednesday, May 01, 2019 6:48:56 PM

Post# of 239
From the MD&A out yesterday
Pg 2
During the recent beta testing, management noted a packaging issue which was resulting in the leaching of contaminants into the test kits; thus, delaying sales of the CompleTest TM units to Q2 2019.
In 2019, FluroTech has several strategic objectives for use of the CompleTestTM as a cannabis and hemp analytical testing device: 1. Commence sales in Canada in Q2 utilizing the internal sales team, and build out a referral program with cannabis experts, and 2. Finalize a low THCa testing protocol for hemp and launch sales to hemp producers in Canada and the U.S.
IPg3
n 2019, FluroTech has several strategic objectives for the development of the CompleTestTM system for biomarking: 1. Submit the biomarker patent application, and 2. Form a strategic alliance with either growers and/or seed to sale tracking companies, to scale the testing of the application of biomarker and integrate with the existing tracking systems


...numerous police forces are hesitant to pursue drug impairment charges and that constitutional challenges are in progress with respect to the new laws on drug impairment which is slowing the demand for roadside screening equipment. As the Company has a number of other development initiatives in progress and because there is much controversy in the roadside testing market it has conscientiously reassigned its development team to other high value projects until a later date.

There was $5M in cash at Dec 31.